Top Page
Capstone Therapeutics
(NASDAQ:CAPS)
Capstone Therapeutics (CAPS) vs. SPDR S&P 500 ETF (SPY)
Capstone Therapeutics Business Overview & Revenue Model
Capstone Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.38M | 44.88M | 48.35M | 61.56M | 66.74M | 45.45M |
| Gross Profit | 9.52M | 9.57M | 9.61M | 16.53M | 16.32M | 10.94M |
| EBITDA | -1.28M | -121.00K | -1.75M | 4.23M | 5.02M | 2.64M |
| Net Income | -4.20M | -2.56M | -3.82M | 2.31M | 3.92M | 10.46M |
Balance Sheet | ||||||
| Total Assets | 51.88M | 47.22M | 52.70M | 65.21M | 60.85M | 54.87M |
| Cash, Cash Equivalents and Short-Term Investments | 773.00K | 11.00K | 52.00K | 23.00K | 50.00K | 1.00 |
| Total Debt | 14.91M | 16.61M | 20.33M | 28.80M | 28.34M | 20.81M |
| Total Liabilities | 8.64M | 50.28M | 23.58M | 31.88M | 31.78M | 25.77M |
| Stockholders Equity | 26.27M | -3.06M | 2.44M | 33.33M | 29.08M | 29.11M |
Cash Flow | ||||||
| Free Cash Flow | 1.10M | 3.70M | 1.24M | -3.06M | 2.55M | 639.00K |
| Operating Cash Flow | 1.14M | 3.82M | 1.45M | -2.89M | 3.72M | 642.00K |
| Investing Cash Flow | -39.00K | -120.00K | -208.00K | -173.00K | -931.00K | -3.00K |
| Financing Cash Flow | -332.00K | -3.74M | -1.21M | 3.04M | -2.74M | -697.00K |
Capstone Therapeutics Technical Analysis
Capstone Therapeutics Risk Analysis
Capstone Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
| ― | $8.78M | -0.08 | -12.98% | ― | -0.97% | 64.07% | |
| ― | $89.84K | >-0.01 | ― | ― | ― | ― | |
| ― | $81.32M | -1.11 | -175.12% | ― | ― | 23.17% | |
| ― | $24.62M | -0.36 | -104.07% | ― | ― | 1.66% | |
| ― | $16.42M | -0.22 | -9690.24% | ― | 1943.07% | 80.97% | |
| ― | $20.91M | ― | ― | ― | ― | 87.87% |
Capstone Therapeutics Corporate Events
Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes. On October 22, 2025, Capstone issued a second convertible note worth $3,545,712.42, convertible into common stock at a price of $1.10 per share. The company received gross proceeds of $3,250,000 from this issuance and plans to file a registration statement with the SEC for the resale of the stock. Joseph Gunnar & Co., LLC acted as the sales agent for this financing.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
On September 30, 2025, Capstone Holding Corp. entered into an Exchange Agreement with Brookstone entities to exchange $1.9 million in debt for newly issued non-convertible preferred equity, Series Z Preferred shares. This strategic move, approved by the Board, strengthens Capstone’s balance sheet by eliminating targeted debt and reducing interest expenses by over $170,000, without diluting common shareholders. The transaction enhances Capstone’s financial flexibility, positioning the company for potential accretive acquisitions and signaling confidence in its long-term cash flows.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
On August 15, 2025, Capstone Holding Corp. announced a membership interest purchase agreement to acquire all issued and outstanding membership interests in Carolina Stone Holdings, LLC, and its subsidiary, Carolina Stone Distributors, LLC, for a total of $2,625,000 in cash, a seller note of $1,250,000, and an earn-out agreement. This acquisition, expected to close on August 29, 2025, aims to enhance Capstone’s market presence in the stone products industry by integrating Carolina Stone’s operations into its portfolio.
Capstone Holding Corp., formerly known as Capstone Therapeutics Corp., is a holding company primarily operating through its subsidiary TotalStone, LLC, which distributes masonry stone products for residential and commercial construction across the Midwest and Northeast United States.
Capstone Holding Corp. entered into a securities purchase agreement with an institutional investor on July 29, 2025, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On August 14, 2025, the company and the buyer agreed to reduce the conversion price of the first issued note from $1.72 to $1.00, effective August 15, 2025, with a conversion limit of $1,363,736 at the new price.
Capstone Holding Corp. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for this delay is the company’s ongoing efforts to complete its financial statements and disclosures, coupled with the need for additional time by its independent accounting firm to review the financial data. Capstone anticipates filing the report within five calendar days following the original due date. The company does not expect any significant changes in its financial results compared to the same period last year. Capstone is actively working to ensure compliance, with the notification signed by CEO Matthew E. Lipman.
On July 29, 2025, Capstone Holding Corp. entered into a securities purchase agreement with an institutional investor to issue senior secured convertible notes, initially raising $3 million out of a $10 million facility, to support its M&A strategy. This financing will primarily fund the acquisition of a Southeast U.S.-based distributor, marking Capstone’s expansion into a high-growth construction market, while maintaining capital structure and aligning with its long-term strategy of investing in high-quality, earnings-accretive acquisitions.